Optimal adjuvant endocrine therapy for breast cancer

Affiliations

¹ Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.
² Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. Electronic address: ndavidson@fredhutch.org.

Comment

Rachel L Yung et al. Lancet Oncol. 2021 Oct.

. 2021 Oct;22(10):1357-1358.

doi: 10.1016/S1470-2045(21)00420-4. Epub 2021 Sep 17.

¹ Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.
² Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA. Electronic address: ndavidson@fredhutch.org.

No abstract available

Conflict of interest statement

We declare no competing interests.

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, Campadelli E, Cognetti F, Frassoldati A, Michelotti A, Mura S, Urracci Y, Sanna G, Gori S, De Placido S, Garrone O, Fabi A, Barone C, Tamberi S, Bighin C, Puglisi F, Moretti G, Arpino G, Ballestrero A, Poggio F, Lambertini M, Montemurro F, Bruzzi P; Gruppo Italiano Mammella investigators. Del Mastro L, et al. Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17. Lancet Oncol. 2021. PMID: 34543613 Clinical Trial.